Uncertain Future For Orphazyme After EMA Snub

Agency Set To Reject Arimoclomol For Niemann-Picks Type C

The EMA's medicines evaluation committee has told Orphazyme it will not approve the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.

mermaid
Denmark's Orphazyme left to reflect on EMA's rejection • Source: Alamy

The future of Orphazyme A/S is up in the air after regulators in the EU followed the stance of their US peers in rejecting arimoclomol, the Danish biotech's treatment for the ultra-rare disorder Niemann-Pick disease type C (NPC).

Orphazyme has been in close contact with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

More from Scrip

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.